Department of Respiratory Medicine, Hvidovre Hospital & University of Copenhagen, Denmark
Background and Aim:
Long-acting bronchodilators are the mainstay of pharmacological treatment for patients
with chronic obstructive pulmonary disease (COPD). The aim of this review is to provide an overview of the clinical
studies evaluating the safety and efficacy of inhaled aclidinium bromide, a novel long-acting anticholinergic
bronchodilator, for the treatment of COPD.
This systematic review explored the efficacy and safety of aclidinium bromide in comparison with placebo and
other long-acting bronchodilators for treatment of moderate to severe COPD. Randomised controlled trials were identified
through systematic searches of different databases of published trials.
Ten trials (3.922 participants) were included. Aclidinium bromide appears to be a safe and well-tolerated long-acting
anti-cholinergic bronchodilator with a relatively fast onset of action. Compared with other long-acting
bronchodilators, including tiotropium bromide, aclidinium bromide leads to at least similar clinically important
improvements in level of FEV1, health status, use of rescue medication, and day-time dyspnea scores in patients suffering
from moderate to severe COPD. With twice-daily dosing, aclidinium bromide may have clinically important effect on
night-time symptom scores in COPD patients, but further studies are needed in order to permit valid conclusions with
regard to this point. The effect of aclidinium bromide on exercise tolerance, as assessed by exercise endurance time, and
dynamic hyperinflation in patients with moderate to severe COPD seems to be at least comparable to other long-acting
bronchodilators, incl. tiotropium bromide and indacaterol. Aclidinium bromide might reduce the rate of exacerbations in
COPD patients, but conclusions must await further long-term controlled trials.
Aclidinium bromide has effects on relevant COPD outcome measures, including level of FEV1, similar to
other long-acting bronchodilators, and therefore seems to have the potential for a significant role in the future
management of moderate to severe COPD.
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
* Address correspondence to this author at the Department of Respiratory
Medicine, 253 Hvidovre Hospital, Hvidovre Hospital, DK-2650 Hvidovre,
Denmark; Tel: +45 3862 6089; Fax +45 4583 6331;